JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide
JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s Ministry of Food and Drug...
Search results for "Phase 3 trial"
VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial
Otsuka Pharmaceutical’s VOYXACT (active ingredient: sibeprenlimab) demonstrated long-term kidney protection by maintaining kidney function over a...
Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy
CKD-339, an essential hypertension treatment under development by Chong Kun Dang, is advancing into a Phase 3 clinical...
Placebo Outperforms TG-C: Data Errors and Stock Volatility Cloud Kolon TissueGene’s Phase 3 Trial
Kolon TissueGene’s knee osteoarthritis cell and gene therapy, TG-C, has failed to achieve statistical significance on...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data
HLB Innovation announced on July 23 that its U.S. subsidiary, Verismo Therapeutics, has expanded the Phase 1 clinical...
Fast-Tracking Biosimilars: South Korea to Waive Phase 3 Clinical Trials Under New Guidelines
South Korean regulators have revised requirements to significantly reduce the time and financial burden of biosimilar...
MediPost Begins Pivotal U.S. Phase 3 Trial for Regenerative Knee Therapy Cartistem
South Korean biotechnology company MediPost has entered full-scale Phase 3 clinical testing in the United States for...
GC Biopharma to Conduct Phase 3 Clinical Trial for Two-Dose Chickenpox Vaccine in South Korea
GC Biopharma’s chickenpox vaccine, Barycela Inj., is set to enter a Phase 3 clinical trial in South Korea to confirm...
GC Wellbeing’s Laennec Injection Clears Phase 3 Hurdle for IV Drip Use, Boosting Growth Prospects
GC Wellbeing announced on June 16 that it has secured topline results demonstrating that its chronic liver disease...